| 22nd week of 2010 patent applcation highlights part 54 |
| Patent application number | Title | Published |
|---|
| 20100137385 | Insecticidal Substituted Amino Heterocyclic and Heteroaryl Derivatives - Certain substituted amino heterocyclic and heteroaryl derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula (I): wherein R, R | 2010-06-03 |
| 20100137386 | TNIK INHIBITOR AND THE USE - The present invention relates to compositions and methods for the treatment of cancer patients with Traf2- and Nck-interacting kinase (TNIK) inhibitors. More particularly, the present invention relates to pharmaceutical compositions comprising TNIK inhibitor and a pharmaceutically acceptable carrier, and to methods for treating the TNIK inhibitor administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. | 2010-06-03 |
| 20100137387 | BETA-KETO-AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS - This invention relates to novel β-keto-amide derivatives that are found to be potent modulators of ion channels, and in particular potassium channels and chloride channels, and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to the modulation of potassium channels. | 2010-06-03 |
| 20100137388 | Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof - The present invention provides for therapies characterized in part by co-administration or combination of antibiotic agents with medicinal compositions comprising as the pro-antibiotic active ingredient either a compound represented by a formula [I] or a pharmaceutically acceptable composite thereof; [wherein X represents oxygen, sulfur, NH, or N-alkyl; R | 2010-06-03 |
| 20100137389 | TOPICAL FORMULATION - The invention relates to composition and related therapeutic methods including at least one antihyperthyroid drug formulated for transdermal administration. Because the formulation is formulated for transdermal administration, the formulation is easier to administer than existing formulations which are administered orally to animals. Issues surrounding transdermal administration versus oral administration have also been resolved allowing the agent to remain stable during storage and retain a high level of efficacy. | 2010-06-03 |
| 20100137390 | 1,3-Dihydroimidazole-2-Thione Derivatives as Inhibitors of Dopamine-Beta-Hydroxylase - Compounds of formula I and a method for their preparation are described, where R | 2010-06-03 |
| 20100137391 | Histamine H3 Agonist for use as Therapeutic Agent for a Lipid/Glucose Metabolic Disorder - Disclosed are: novel use of an agonist histamine receptor H3 (e.g., Imetit) for prevention of obesity or the reduction of food intake; a method for evaluation of a compound for use as a therapeutic agent targeted to histamine receptor HR protein; and a compound provided by the method. | 2010-06-03 |
| 20100137392 | THERAPY FOR THE TREATMENT OF DISEASE - Disclosed herein are pharmaceutical compositions comprising oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition. | 2010-06-03 |
| 20100137393 | PREDICTION AND PROPHYLACTIC TREATMENT OF TYPE 1 DIABETES - An in vitro method for predicting the onset of type 1 diabetes (T1 D) in a subject, comprises the steps of: (a) measuring the concentration of at least one amino acid, amino acid derivative or amino acid metabolite in a biological sample taken from the subject; (b) determining the subject's HLA genotype; (c) assigning the subject's genetic risk of developing T1 D on the basis of the subject's HLA genotype; (d) combining the information obtained in step (a) with the information in step (c); and (e) predicting the likelihood of onset of T1 D based upon the combination of step (d). The diagnostic method can be used to select target subjects for T1 D prophylactic treatment, and as part of a T1 D preventative treatment regime for neonates having a likelihood of developing childhood T1 D. | 2010-06-03 |
| 20100137394 | PYRAZOLE INHIBITORS OF WNT SIGNALING - The invention provides inhibitors of Wnt signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein R1 to R7 and Z are as defined herein. | 2010-06-03 |
| 20100137395 | Process for the Sulfinylation of a Pyrazole Derivative - The present invention relates to a process for the sulfinylation of a pyrazole derivative, characterized in that 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-3-carbonitrile (II) is reacted with a sulfinylating agent selected from trifluoromethylsulfinic acid, trifluoromethylsulfinic acid anhydride, and a trifluoromethylsulfinate alkaline or alkaline earth metal salt and mixtures of the acid and/or the salt(s), in the presence of at least one amine acid complex wherein the amine(s) are selected from tertiary amines and the acid(s) are selected from hydrofluoric, hydrochloric, hydrobromic and hydroiodic acid and sulfonic acid derivatives, and with the addition of a halogenating agent. | 2010-06-03 |
| 20100137396 | TREATMENT OF ESOPHAGEAL HIGH GRADE DYSPLASIA USING PHOTODYNAMIC THERAPY - A method for treatment of esophageal high grade dysplasia comprising the steps of: injecting HPPH in a physiologically compatible medium into a patient having high grade dysplasia tissue to provide a dose level of 3 through 5 mg/m | 2010-06-03 |
| 20100137397 | Chemical Compounds - A compound of the formula (1) or a pharmaceutically-acceptable salt: possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity such as 2 diabetes. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described. | 2010-06-03 |
| 20100137398 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL CANCERS - The present invention relates to the use of an HDAC inhibitor for the preparation of a medicament for the treatment of gastrointestinal cancers; a method of treating a warm-blooded animal, especially a human, having gastrointestinal cancer, comprising administering to said animal a therapeutically effective amount of an HDAC inhibitor, especially a compound of formula (I) as defined herein; and to a pharmaceutical composition and a commercial package. | 2010-06-03 |
| 20100137400 | PHARMACEUTICAL FORMULATION CONTAINING AN HMG-COA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF - The present invention relates to improved pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an HMG-CoA reductase inhibitor, and more particularly Fluvastatin, Atorvastatin or salts thereof in combination with a linear sulphated polysaccharide such as Carrageenan and a method for the preparation thereof. | 2010-06-03 |
| 20100137401 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess. | 2010-06-03 |
| 20100137402 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION - The subject of the present invention is compounds corresponding to formula (I): | 2010-06-03 |
| 20100137403 | METHOD FOR ENHANCING COGNITION OR INHIBITING COGNITIVE DECLINE - A method for enhancing cognition or inhibiting cognitive decline in a subject comprises selecting a Ca | 2010-06-03 |
| 20100137404 | Compositions and Methods for Altering Gene Expression - Compositions and methods for regulating gene expression in a growing animal are disclosed. | 2010-06-03 |
| 20100137405 | RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA) - The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of cyclic nucleotide type 4 phosphodiesterase (PDE4B) gene expression and/or activity, including PDE4B1, PDE4B2, and PDE4B3 gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in cyclic nucleotide type 4 phosphodiesterase (PDE4B) gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions, including but not limited to IL-6, IL-I, IL-8, IL-15, TNF-alpha and matrix metalloproteinases (MMPs), such as MMP-I, MMP-2, MMP-3, MMP-9 and MMP-12. Specifically, the invention relates to double stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA), and multifunctional siNA molecules capable of mediating RNA interference (RNAi) against cyclic nucleotide type 4 phosphodiesterase (PDE4B) gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. The present invention also relates to small nucleic acid molecules, such as siNA, siRNA, antisense and others that can inhibit the function of endogenous RNA molecules or RNAi pathway components (RNAi inhibitors), such as endogenous micro-RNA (miRNA) (e.g, miRNA inhibitors) or endogenous short interfering RNA (siRNA), (e.g., siRNA inhibitors) or that can inhibit the function of RISC (e.g., RISC inhibitors), to modulate PDE4B gene expression by interfering with the regulatory function of such endogenous RNAs or proteins associated with such endogenous RNAs (e.g., RISC) including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. Such small nucleic acid molecules are useful, for example, in providing compositions to prevent, inhibit, or reduce inflammatory, respiratory, and autoimmune diseases, traits, and conditions, and/or other disease states associated with PDE4B gene expression or activity in a subject or organism. | 2010-06-03 |
| 20100137406 | RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA) - The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of cyclic nucleotide type 4 phosphodiesterase (PDE4B) gene expression and/or activity, including PDE4B1, PDE4B2, and PDE4B3 gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in cyclic nucleotide type 4 phosphodiesterase (PDE4B) gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions, including but not limited to IL-6, IL-I, IL-8, IL-15, TNF-alpha and matrix metalloproteinases (MMPs), such as MMP-1, MMP-2, MMP-3, MMP-9 and MMP-12. Specifically, the invention relates to double stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA), and multifunctional siNA molecules capable of mediating RNA interference (RNAi) against cyclic nucleotide type 4 phosphodiesterase (PDE4B) gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. The present invention also relates to small nucleic acid molecules, such as siNA, siRNA, antisense and others that can inhibit the function of endogenous RNA molecules or RNAi pathway components (RNAi inhibitors), such as endogenous micro-RNA (miRNA) (e.g., miRNA inhibitors) or endogenous short interfering RNA (siRNA), (e.g., siRNA inhibitors) or that can inhibit the function of RISC (e.g., RISC inhibitors), to modulate PDE4B gene expression by interfering with the regulatory function of such endogenous RNAs or proteins associated with such endogenous RNAs (e.g., RISC) including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. Such small nucleic acid molecules are useful, for example, in providing compositions to prevent, inhibit, or reduce inflammatory, respiratory, and autoimmune diseases, traits, and conditions, and/or other disease states associated with PDE4B gene expression or activity in a subject or organism. | 2010-06-03 |
| 20100137407 | SINGLE-CHAIN CIRCULAR RNA AND METHOD OF PRODUCING THE SAME - The present invention relates to a single-chain circular RNA having a sustained or slow-releasing RNA interference effect, characterized in that the single-chain circular RNA comprises a sense strand sequence, an antisense strand sequence complementary to the sense strand sequence, identical or different two loop sequences between the sense strand and the antisense strand, connecting both strands, wherein the sense strand and the antisense strand are paired to form a stem. | 2010-06-03 |
| 20100137408 | ANTISENSE ANTIBACTERIAL METHOD AND COMPOUND - A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication. The compound binds to a target mRNA with a T | 2010-06-03 |
| 20100137409 | Compositions and Methods for the Treatment of Diseases Associated with Aberrant Cilia Assembly and Regulation - Compositions and methods are provided for identifying agents which have efficacy for the treatment of disorders related to aberrant cilial structure and function, including polycystic kidney disease. | 2010-06-03 |
| 20100137410 | Oncogenic ALL-1 Fusion Proteins for Targeting Drosha-Mediated MicroRNA Processing - Disclosed are compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins. | 2010-06-03 |
| 20100137411 | RAS-MEDIATED EPIGENETIC SILENCING EFFECTORS AND USES THEREOF - The invention relates to methods for inhibiting gene silencing, methods for inhibiting cell proliferation, methods for inhibiting Ras mediated tumor growth, methods for screening for regulators of FAS expression, and methods for identifying inhibitors of Ras mediated tumor growth. | 2010-06-03 |
| 20100137412 | LENTIVIRUS PSEUDOTYPED WITH INFLUENZA HEMAGGLUTININ AND METHODS OF USE - Highly effective pseudotyping of lentiviral vector with influenza HA, NA and M2 packaging gene constructs at the proper ratios. Lentivirus vector pseudotyped with influenza HA, especially pseudotyped with H5 and neuraminidase. Methods of inducing immune responses to influenza antigens or for transducing genes into cells to which influenza antigens bind using such lentivirus vectors. Methods for screening drugs which inhibit influenza infection using lentivirus pseudotyped with HA. | 2010-06-03 |
| 20100137413 | MICRORNAOME - MicroRNAs (miRNAs) are a class of small noncoding RNAs that have important regulatory roles in multicellular organisms. The public miRNA database contains 321 human miRNA sequences, 234 of which have been experimentally verified. To explore the possibility that additional miRNAs are present in the human genome, we have developed an experimental approach called miRNA serial analysis of gene expression (miRAGE) and used it to perform the largest experimental analysis of human miRNAs to date. Sequence analysis of 273,966 small RNA tags from human colorectal cells allowed us to identify 200 known mature miRNAs, 133 novel miRNA candidates, and 112 previously uncharacterized miRNA* forms. To aid in the evaluation of candidate miRNAs, we disrupted the Dicer locus in three human colorectal cancer cell lines and examined known and novel miRNAs in these cells. The miRNAs are useful to diagnose and treat cancers. | 2010-06-03 |
| 20100137414 | Modulation of Factor 11 Expression - Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism. | 2010-06-03 |
| 20100137415 | VECTOR FOR GENE THERAPY - The present invention provides a retroviral vector containing a transcription unit comprising a transcription regulatory sequence and a gene encoding a polypeptide having single-stranded RNA-specific endoribonuclease activity which is placed so that its expression can be controlled by the regulatory sequence, wherein the unit is placed so that the direction of the transcription of mRNA from the unit is opposite to the direction of transcription of the RNA genome of the retroviral vector. By using the vector constructed as described above, viral supernatant showing high gene transfer efficiency can be prepared. The retroviral vector of the present invention is useful for the treatment and/or prevention of cancers and virus infections. | 2010-06-03 |
| 20100137416 | CADHERIN-11-MEDIATED MODULATION OF HAIR GROWTH - The present invention provides for methods of inhibiting hair growth, comprising decreasing the level of CAD1 1 mRNA and/or protein in hair follicle cells of a subject. The present invention further provides for methods of promoting hair growth, comprising increasing the level of CADI 1 mKNA and/or protein in hair follicle cells of a subject. The invention also provides for transgenic animals with aberrancies in CADI 1 expression, and for assay systems (including transgenic animals and cell-based systems) that may be used to identify agents that decrease or increase CADI 1 expression. | 2010-06-03 |
| 20100137417 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses - The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have glucagon receptor antagonist or inverse agonist activity, as well as methods of using these compounds and intermediates and methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising N compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like. | 2010-06-03 |
| 20100137418 | METHOD FOR TREATING ATHEROSCLEROSIS OR RESTENOSIS USING MICROTUBULE STABILIZING AGENT - The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefore. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arterial injury by treatment with a low dose of a microtubule stabilizing agent such as taxol or a water soluble taxol derivative. The low dose used in the present invention prevents artery blockage while minimizing any negative side effects associated with the drug. | 2010-06-03 |
| 20100137419 | ANTI-CANCER AGENT - Disclosed is a novel anti-cancer agent which is less likely to be excreted from a cancer cells and is suitable for the local treatment against a cancer cell. The anti-cancer agent comprises a rotaxane compound represented by chemical formula (I) as an active ingredient. The rotaxane compound is composed of two moieties; namely, a rod-like moiety having a relatively large molecule attached to each of both ends, and a cyclic moiety (a crown ether) into which the rod-like moiety has been inserted. The cyclic moiety cannot be detached from the rod-like moiety, because the rod-like moiety has a relatively large molecule attached to each of both ends and the relatively large molecules serves as a stopper for the detachment. The bond between the two moieties is not a covalent bond. Therefore, the shape of the molecule can be varied readily, and the uptake of the molecule via a receptor becomes relatively difficult. However, once the molecule is introduced into a cancer cell, the proliferation of the cancer cell can be inhibited. | 2010-06-03 |
| 20100137420 | Methods and Compositions for Diagnosis and Treatment of Multiple Sclerosis - Biological markers for multiple sclerosis, and their use in the diagnosis and prognosis of the disease, are described. Also described are methods for treating multiple sclerosis by administering an inhibitor of cathepsin B activity or a neuroprotective composition comprising a modified terpenoid compound. Also described are isolated polypeptide biomarkers, polynucleotides encoding the polypeptide biomarkers, and antibodies that bind specifically to the polypeptide biomarkers. Further described are kits that include the above-mentioned isolated polypeptide biomarkers, the polynucleotides encoding them, or specific antibodies against the polypeptide biomarkers. | 2010-06-03 |
| 20100137421 | SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE - Provided herein are compounds that are inducers of apoptosis activators of caspases and pharmaceutically acceptable derivatives thereof. Also provided are methods of synthesis of the compounds and methods for treatment of diseases in which there is uncontrolled cell growth and spread of abnormal cells, such as cancers, by administering the compounds. | 2010-06-03 |
| 20100137422 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME - Provided is a pharmaceutical composition for the treatment and/or prevention of disease involving metabolic syndromes, comprising (a) a therapeutically effective amount of a particular compound represented by Formula 1 as defined in the specification, or isomer, prodrug, or solvate or thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof. | 2010-06-03 |
| 20100137423 | ANTIOXIDATIVE COMPOSITION CONTAINING ACACIA BARK DERIVATIVE - It is intended to provide a composition which is useful in preventing or treating tumor. Namely, a composition for preventing and/or treating tumor which is characterized by containing a component originating in the bark of a tree belonging to the genus | 2010-06-03 |
| 20100137424 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEBIVOLOL OR A NEBIVOLOL ANALOGUE - The disclosed pharmaceutical compositions for oral administration comprising as the active medicinal ingredient nebivolol, a nebivolol analogue or a pharmaceutically acceptable acid addition salt thereof and a wetting agent. The ratio of the wetting agent to the active ingredient is less than 0.025. The application also relates to methods of preparing these compositions and using said compositions for treating coronary vascular disorders in humans. | 2010-06-03 |
| 20100137425 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS - The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4. | 2010-06-03 |
| 20100137426 | METHOD FOR GENERATING REFERENCE CONTROLS FOR PHARMACOGENOMIC TESTING - Reference controls for use with pharmacogenomic testing, and methods for their identification, preparation, and use, are disclosed. The reference controls can confirm that pharmacogenomic testing correctly identifies individuals that do or do not have the mutation of interest, in both clinical trial and patient treatment settings. The reference controls can be selected to include one or more mutations to be identified, and prescreened to confirm that they bind to one or more of the primers used in the pharmacogenomic testing. The reference controls are human genomic DNA that includes certain identified polymorphisms (mutations) of interest, ideally derived from individuals, pre-selected and optionally properly consented, which have one or more of the polymorphism(s) of interest. The reference controls can be prepared by targeted pre-screening of human patients, by examining the genotype or genetic profile of the patients, isolating cells with the desired mutation, optionally immortalizing the cells, and obtaining DNA from the cells. The prescreening of prospective donors can be targeted based on any of a number of factors, such as genes of interest, mutations within the genes of interest, and membership in a specific ethnic or disease state population. The genomic DNA can be pre-screened for its ability to be detected, using a standard pharmacogenomic test, as including a specific mutation. Examples of mutations of interest include those present in a Phase I or Phase II metabolic enzyme such as CYP2D6, CYP2C19, CYP2C9, CYP2C8, and CYP3A5, CYP3A4, CYP2A6, CYP2B6, UGT1A1, DPD, ERCC1, MDR1, ADH2, NAT1 and NAT2 or any other metabolic or disease gene. | 2010-06-03 |
| 20100137427 | Softgel of NLKJ for treating prostate diseases - A softgel of NLKJ for the treatment of prostate diseases, comprising 0.05˜1.0 g of NLKJ and 0.05˜1.5 mg of an antioxidant, said NLKJ having the following physicochemical parameter: acid value<0.56, iodine value 95.0-107.00, saponification value 185.00-195.00, specific gravity 0.914-0.918 (20° C.), and refractive index 1.470-1.475 (20° C.). The inhibition of the softgel of NLKJ on the growth of prostate cancer in combination with the injection of Lupron is stronger than that of each of them used alone. | 2010-06-03 |
| 20100137428 | OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS - The present invention relates to compounds of formula (I), or salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof. | 2010-06-03 |
| 20100137429 | COMPOSITION FOR TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION - The present invention provides a composition for transdermal or transmucosal administration, which is useful as an anti-Alzheimer's drug, an antiparkinson drug, an antidepressant, a psychoactive drug, or a therapeutic agent for drug dependence. The composition for transdermal or transmucosal administration comprising an effective dose of a racemate or an optically acceptable substance of 1-(benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable salt thereof and a vehicle, which can be administered without an invasion of skin and mucous membrane, is an excellent agent serving as an anti-Alzheimer's drug, an antiparkinson drug, an antidepressant, a psychoactive drug or a therapeutic agent for drug dependence, which can allow its active ingredient in a sufficient effective amount to stably arrive, through the skin and mucous membrane, at a body or a brain and is free of disadvantages such as a reduction in an active component caused by a first pass effect in a liver, as well as pains, damages or infections. | 2010-06-03 |
| 20100137430 | TREATING ANDROGEN DECLINE IN AGING MALE (ADAM)-ASSOCIATED CONDITIONS WITH SARMS - This invention provides methods for treatment and inhibition of a male subject having an Androgen Decline in Aging Male (ADAM)-associated condition, for example sexual dysfunction, decreased sexual libido, erectile dysfunction, hypogonadism, sarcopenia, osteopenia, osteoporosis, an alteration in cognition and mood, depression, anemia, hair loss, obesity, muscle loss, dry eye, memory loss, benign prostate hyperplasia and/or prostate cancer, by administering to the subject a selective androgen receptor modulator (SARM) compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, pro-drug, polymorph, crystal, or any combination thereof. | 2010-06-03 |
| 20100137431 | USE OF SUBSTANCES THAT ACT AS CASCADE INHIBITORS OF THE RAF/MEK/ERK SIGNAL CASCADE, FOR PRODUCING A MEDICAMENT TO TREAT DNA AND RNA VIRUSES - The invention consists in that substances acting as cascade inhibitors of the Raf/MEK/ERK signaling pathway, in particular MEK inhibitors, are used for the production of a drug for the preventive and antiviral therapy against DNA and RNA viruses, in particular against intranuclear-replicating negative strand RNA viruses, for instance influenza or Borna disease viruses. | 2010-06-03 |
| 20100137432 | OPHTHALMIC COMPOSITION COMPRISING A PROSTAGLANDIN - The present invention relates to a pharmaceutical composition suitable for ophthalmic use comprising one or more prostaglandin derivatives or salts, a stabilizing amount of polyethylene glycol hydroxystearate and pharmaceutically acceptable vehicle. | 2010-06-03 |
| 20100137433 | Production of Rosmarinic Acid from Spearmint and uses Thereof - The present invention provides plants and plant tissues of spearmint ( | 2010-06-03 |
| 20100137434 | Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer - The present disclosure relates to the discovery that compounds of the invention, particularly 3-bromopyruvate and related compounds, can be safely administered at concentrations effective for the treatment of cancer when formulated with an acidity of greater than or equal to pH of 2 and less than or equal to a pH of 6. Disclosed herein are novel and improved methods and compositions for the treatment of cancer using 3-halopyruvate and related compounds. | 2010-06-03 |
| 20100137435 | Monoacetyldiacylglycerol Derivative for the Treatment of Sepsis - The uses of mono acetyl diacyl glycerol derivatives extracted from deer antler for immunomodulating agent disclosed. Medical supplies and health foods containing the same as an effective ingredient also disclosed. Mono acetyl diacyl glycerol derivatives shows significantly effect for immuno modulation including immune enhancing. In the case of inducing cancer in a hamster by injecting cancer cell line, cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against caner cell. Also in the case of mouse induced septic shock, it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect of apoptosis. Therefore, mono acetyl diacyl glycerol derivatives according to the present invention can be effectively used for an immunomodulating agent, a sepsis treatment, a cancer treatment, and a health food for an immune modulation or the prevention of cancer. | 2010-06-03 |
| 20100137436 | Bipolar trans carotenoid salts and their uses - The invention relates to trans carotenoid salt compounds, methods for making them, methods for solubilizing them and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans. | 2010-06-03 |
| 20100137437 | Composition for Inactivating an Enveloped Virus - The present invention relates generally to the field of prevention of diseases caused by enveloped viruses. More particularly, this invention concerns a composition for inactivating an enveloped virus comprising at least one non phospholipid Lipid Vesicle (nPLV) able to interact with said enveloped virus and an agent that enhances the lipid exchange between said nPLV and the membrane of said enveloped virus. | 2010-06-03 |
| 20100137438 | ISOVALINE FOR TREATMENT OF PAIN - The invention provides for the use of isovaline or a pharmaceutically acceptable salt thereof for the treatment of Pain in a mammalian subject in some preferred embodiments, the invention provides for the treatment of acute and chronic Pain syndromes where other drug therapies have limited efficacy or unacceptable toxicity in said subject. | 2010-06-03 |
| 20100137439 | USE OF AMINOLEVULINIC ACID AND DERIVATIVES THEREOF - The invention provides the use of a photosensitiser which is 5-aminolevulinic acid (5-ALA) or a derivative (e.g. an ester) of 5-ALA, or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitiser; and (b) photoactivating said photosensitiser, and wherein side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm | 2010-06-03 |
| 20100137440 | LYSINE RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH LYSINE RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH LYSINE RIBOSWITCHES - The lysine riboswitch is a target for antibiotics and other small molecule therapies. Compounds can be used to stimulate, active, inhibit and/or inactivate the lysine riboswitch. | 2010-06-03 |
| 20100137441 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS - Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione. | 2010-06-03 |
| 20100137442 | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment - Sustained release particulate oral dosage forms of (R)-baclofen prodrugs and methods of treating a disease comprising orally administering such dosage forms are disclosed. | 2010-06-03 |
| 20100137443 | Ibuprofen for Topical Administration - Set forth herein is a preparation of ibuprofen (2-(4-isobutylphenyl)propionic acid) in the free acid form that is suitable for topical administration. The topical ibuprofen formulation is prepared by dissolving the free acid form of ibuprofen, or preparing a homogeneous suspension of the free acid form of ibuprofen, in the presence of a pharmaceutically acceptable solvent so as to produce a topical drug formulation compatible with the penetration of 2-(4-isobutylphenyl) propionic acid through the skin tissue. Topical formulations of ibuprofen can be based on a pharmaceutically acceptable solvent such as, e.g., a pyrrolidone solvent or dimethylacetamide. | 2010-06-03 |
| 20100137444 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES - The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents. | 2010-06-03 |
| 20100137445 | PLANT DISEASE CONTROL AGENT, AND PLANT DISEASE CONTROL METHOD - Disclosed is a plant disease control agent comprising an amide compound represented by the formula (1) as an active ingredient. | 2010-06-03 |
| 20100137446 | NAPHTHALENE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Compounds of formula (I): | 2010-06-03 |
| 20100137447 | METHOD FOR THE PRODUCTION OF ADSORBATES OF A RASAGILINE SALT HAVING A WATER-SOLUBLE ADJUVANT - The present invention relates to an adsorbate of a pharmaceutically compatible rasagiline salt comprising at least one pharmaceutically compatible adjuvant, wherein the at least one pharmaceutically compatible adjuvant is a water-soluble, organic solvent and the rasagiline salt is present in the adsorbate as an amorphous substance. | 2010-06-03 |
| 20100137448 | Methods for Treating Neuropsychiatric Disorders with NMDA Receptor Antagonists - The present invention relates to compositions and methods for treating a human patient afflicted with a neuropsychiatric disorder. Specifically, the invention provides for compositions and methods of modulating or antagonizing the activity of neuronal NMDA receptors, wherein such antagonistic activity is capable of modulating the glutamate induced excitatory response of the neurons, thereby inhibiting an excitotoxic effect, promoting a neurotrophic effect, and thereby providing a therapeutic effect that treats the neuropsychiatric disorder. | 2010-06-03 |
| 20100137449 | SUBSTITUTED 1,3-CYCLOPENTADIONE MULTI-TARGET PROTEIN KINASE MODULATORS OF CANCER, ANGIOGENESIS AND THE INFLAMMATORY PATHWAYS ASSOCIATED THEREWITH - Compounds and methods for multi-targeted protein kinase modulation for angiogenesis, cancer treatment or the inflammatory pathways associated with those conditions are disclosed. The compounds and methods disclosed are based on substituted 1,3-cyclopentadione compounds. | 2010-06-03 |
| 20100137450 | PROCESS FOR THE PREPARATION OF AQUEOUS FORMALDEHYDE SOLUTIONS - Aqueous formaldehyde solutions are prepared and the formaldehyde content of the aqueous formaldehyde solutions produced is determined by an online analytical method. The desired formaldehyde content can subsequently be established by addition of water so that an aqueous formaldehyde solution having a defined formaldehyde content (formalin) is obtained. | 2010-06-03 |
| 20100137451 | COMPOSITIONS AND METHODS FOR TREATING HOOF DISEASES - The present invention is generally directed to compositions and methods for the treatment of an infectious disease of the foot of an animal. One aspect of the invention is directed to a method for preventing and/or treating one or more infectious diseases of the hoof in animals, comprising: preparing a copper-free and zinc-free composition comprising at least one cross-linking agent, wherein the cross-linking agent is not formaldehyde; and administering the composition to a lower leg and hoof area of said animal to prevent and/or treat said one or more infectious diseases. Another aspect of the invention is directed to a copper-free and zinc-free composition for the treatment and/or prevention of one or more infectious diseases of the hoof in animals, comprising at least one cross-linking agent, wherein said cross-linking agent is not formaldehyde. The present invention is also directed to a method for treating and/or preventing papillomatous digital dermatitis in an ungulate, comprising: preparing a copper-free and zinc-free composition comprising at least one cross-linking agent and at least one quaternary ammonium compound; and spraying or applying in a foam a therapeutically effective amount of said composition to a lower leg and hoof area of said ungulate in order to treat and/or prevent said papillomatous digitial dermatitis. | 2010-06-03 |
| 20100137452 | AQUEOUS COMPOSITIONS HAVING PROTECTED HYDROPHILIC ACTIVES - Aqueous compositions comprising hydrophilic actives and block copolymers comprising at least one block of copolymerized ethylene oxide and at least one block of a polymerized alkylene oxide, the alkylene comprising at least 4 carbon atoms, are described, along with methods of stabilizing hydrophilic actives and methods of increasing compatibility among hydrophilic actives. | 2010-06-03 |
| 20100137453 | Polyurea Product as Thixotropic Rheology Modifying Agent - A thixotropic agent comprising a first polyurea reaction product of a first polyisocyanate with a first amine and a second polyurea reaction product of a second polyisocyanate with a second amine different from the first polyurea reaction product precipitated in the presence of the colloidal particles of the first reaction product. | 2010-06-03 |
| 20100137454 | Silicone Polymer Emulsions - Silicone oil-in-water emulsions containing a polysiloxane containing polymer is prepared by first preparing a polysiloxane containing polymer by the polymerisation of siloxane containing monomers and/or oligomers in the presence of an inert organopoly siloxane and/or an organic fluid, a suitable catalyst and optionally an end-blocking agent; and quenching the reaction if required. If required one or more surfactants may be introduced into the polysiloxane containing polymer to form a homogenous oil phase. Water is then added (in an amount of 0.1-10 percent by weight based on total oil phase weight) to the homogenous oil phase to form a water-in-oil emulsion. Shear is applied to the water-in-oil emulsion to cause inversion of the water-in-oil emulsion to an oil-in-water emulsion. Finally, if required the oil-in-water emulsion can be diluted by adding more water. | 2010-06-03 |
| 20100137455 | N-VINYLCAPROLACTAM-BASED COPOLYMERS AND THE USE THEREOF AS SOLUBILIZERS - Copolymers for use in solubilizing substances which are insoluble in water, substances which are only sparingly soluble in water, and combinations thereof; such copolymers comprising: (a) 60 to 99% by weight of N-vinylcaprolactam; and (b) 1 to 40% by weight of at least one other monomer selected from the group consisting of: C | 2010-06-03 |
| 20100137456 | Polysaccharides functionalized by tryptophan derivatives - The present invention relates to novel polysaccharide derivatives, predominantly comprising glycosidic bonds of (1,4), (1,3) and/or (1,2) type, functionalized by at least one tryptophan derivative. It also relates to processes for the synthesis thereof, to their uses as pharmaceutical excipient and to the pharmaceutical compositions comprising them. | 2010-06-03 |
| 20100137457 | METHOD FOR CONVERSION OF ATMOSPHERIC CARBON DIOXIDE INTO USEFUL MATERIALS - A method for converting carbon dioxide in a gaseous environment, including air into useful materials by use of renewable energy sources which comprises:
| 2010-06-03 |
| 20100137458 | GAS TO LIQUIDS PLANT WITH CONSECUTIVE FISCHER-TROPSCH REACTORS AND HYDROGEN MAKE-UP - A process for converting synthesis gas to hydrocarbons, using a Fischer-Tropsch synthesis. Two F-T reactors are used in series with water removal between them and additional hydrogen added to the second reactor in an embodiment. | 2010-06-03 |
| 20100137459 | MULTI-ZONE REFORMING METHODS AND APPARATUS FOR CONVERSION OF DEVOLATILIZED BIOMASS TO SYNGAS - The present invention provides improved methods and apparatus for producing syngas from any carbon-containing feed material. In one aspect, a multi-zone reformer system is provided. A first reaction zone can reduce the presence of refractory tars, while a second reaction zone in communication with the first reaction zone can steam-reform methane and other components from the first reaction zone, to generate high-quality syngas suitable for conversion to liquid fuels, such as ethanol. Other embodiments employ a plurality of reaction zones for added system functionality. | 2010-06-03 |
| 20100137460 | ELECTROCHEMICAL DEVICES CONTAINING ANIONIC-EXCHANGE MEMBRANES AND POLYMERIC IONOMERS - Electrochemical devices allowing high performances in resistance, thermal stability and conductivity comprising polymeric ionic exchange membranes and ionomers are described. | 2010-06-03 |
| 20100137461 | (Pentaphenyl)phenyl Group Containing Compound, Polymeric Derivative Thereof And Method For Forming The Same - The present invention discloses an iridium complex containing a (pentaphenyl)phenyl ligand, having the following general equation: | 2010-06-03 |
| 20100137462 | SEPARATING DEVULCANIZED RUBBER - A method for separating a polymer from carbon black in devulcanized rubber, the method comprising steps of inserting devulcanized rubber into a bath of a solvent, dissolving a polymer out of the devulcanized rubber and into a solution of the solvent and the polymer, removing the solution from the bath without disturbing an un-dissolved residue comprising carbon black, and recovering the un-dissolved residue. | 2010-06-03 |
| 20100137463 | POLYESTER WITH CAUSTIC MATERIAL MIXING METHODS AND MIXING REACTORS - The invention relates to a method for mixing a polyester with caustic material including providing a polyester, preferably PET, mixing the polyester with the caustic material; and heating the mixture in temperature stages defined as a function of a reaction sequence of the reaction between the PET and the caustic material. | 2010-06-03 |
| 20100137464 | POROSITY CONTROL WITH POLYHEDRAL OLIGOMERIC SILSESQUIOXANES - The use of nanostructured chemicals based on polyhedral oligomeric silsesquioxanes (POSS) and polyhedral oligomeric silicates (POS) are used to control porosity in organic and inorganic media. The precisely defined nanoscopic dimensions of this class of chemicals enables porosity to be both created (increased) or reduced (decreased) as desired. The thermal and chemical stability of the POSS/POS nanostructures and the ability of these nano-building blocks to be selectively placed or rationally assembled with both inorganic and organic material mediums allow tailoring of porosity. | 2010-06-03 |
| 20100137465 | PHOSPHATE ESTER FLAME RETARDANT AND RESINS CONTAINING SAME - Certain cyclic phosphate ester compounds useful, inter alia, as halogen-free flame-retardant compounds, are disclosed. The compounds are particularly useful for providing flame retarded polyurethane foams. (I) | 2010-06-03 |
| 20100137466 | POLYPROPYLENE RESIN FOAMED BEAD AND MOLDED ARTICLE THEREFORM - Improved polypropylene resin foamed beads that without detriment to the excellence in properties, such as compression properties and heat resistance, characterizing the polypropylene resin foamed beads, can provide a polypropylene resin foamed bead molded article with equal properties by an molding conducted at low heating temperature. There are disclosed polypropylene resin foamed beads composed of a polypropylene resin of 115 to 135° C. melting point and 500 MPa or higher Olsen flexural modulus. The amount of ash at the surface of the foamed beads is 3000 wt. ppm or less (including 0). With respect to the foamed beads, in the first DSC curve obtained by heating 1 to 3 mg of polypropylene resin foamed beads from room temperature to 200° C. at a temperature elevation rate of 10° C./min by the use of a differential scanning calorimeter, there appear not only one or more endothermic peak (Pa) having the peak temperature within a temperature zone not higher than the melting point of the resin but also one or more endothermic peak (Pb) having the peak temperature within a temperature zone exceeding the melting point of the resin and not lower than 130° C. The total calorific value of the endothermic peak (Pb) is in the range of 2 to 12 J/g. Further, there is disclosed a foamed bead molded article obtained by molding the above foamed beads. | 2010-06-03 |
| 20100137467 | POLYURETHANE FOAM CONTAINING FLAME-RETARDANT MIXTURE - The invention relates to flame retarded polyurethane foam containing, inter alia, an effective flame retarding amount of a non-halogen flame-retardant mixture wherein said foam is capable of meeting or exceeding stringent flame retardancy criteria. | 2010-06-03 |
| 20100137468 | DENTAL COMPOSITION BASED ON SILICONE CROSSLINKABLE BY CATION PROCESS - The invention concerns dental compositions. Said composition comprises (1) a silicone crosslinkable and/or polymerizable by cation process; (2) an efficient amount of at least an initiator such as onium borate; (3) at least a photosensitizer; and (4) a dental filler present in the composition in a proportion of at least 10 wt. % relative to the composition total weight. Said dental compositions are useful for making dental prostheses or for dental restoration. | 2010-06-03 |
| 20100137469 | AZIRIDINE-FUNCTIONAL PHOTOACTIVE CROSSLINKING COMPOUNDS - A photoactive compound that is the Michael addition reaction product of an aziridine compound and a photoinitiator-functional (meth)acrylate is described. The compound can be used to crosslink (meth)acrylic polymers via a hydrogen abstracting or an alpha-cleavage mechanism. | 2010-06-03 |
| 20100137470 | Stabilized Elastomer Dispersions - This invention pertains to neutralized silicone elastomer dispersions and methods for making neutralized silicone elastomer dispersions. This invention also pertains to compositions comprising the neutralized silicone elastomer and an acid reactive compound. The silicone elastomer dispersion are neutralized typically by blending the silicone elastomer dispersion with a base such as sodium bicarbonate or by adding a basic neutralizing agent to one or more of the raw materials used to make the silicone elastomer dispersion and removing the basic neutralizing agent by filtration or any other suitable means. | 2010-06-03 |
| 20100137471 | Compositions Containing Fast-Leaching Plasticizers For Improved Performance Of Medical Devices - Medical implants containing a temporary plasticizer, methods of producing such implants, and methods of using the implants in treating a disease, or ameliorating one or more symptoms thereof, in a subject are provided. | 2010-06-03 |
| 20100137472 | ANTIMICROBIAL COATING COMPOSITIONS - Antimicrobial compositions and methods are disclosed. The antimicrobial compositions are particularly useful in providing antimicrobial capability to a wide-range of medical devices. In one aspect, the invention relates to a mild solvent coating using acrylate-type mild solution coating. These compositions include rheological modifiers as necessary. The compositions also include antimicrobial agents, which may be selected from a wide array of agents. Representative antimicrobial agents include cetyl pyridium chloride, cetrimide, alexidine, chlorexidine diacetate, benzalkonium chloride, and o-phthalaldehyde. Additionally, the compositions comprise one or more suitable mild solvents, such as a low molecular weight alcohol, alkane, ketone, and combinations thereof. | 2010-06-03 |
| 20100137473 | AQUEOUS RESIN COMPOSITIONS AND METHODS FOR CEMENT REPAIR - A composition for repairing voids or cracks in a cement sheath or plug comprises an aqueous epoxy resin, a hardener, an alkali-swellable material and an aqueous carrier fluid. The particle size of the alkali-swellable material is preferably smaller than 200 nanometers, thereby allowing the composition to penetrate cracks as small as 60 micrometers. A method for repairing voids or cracks in a cement sheath, thereby restoring zonal isolation, comprises preparing the composition, injecting the composition into voids or cracks in a cement sheath or plug and allowing the composition to viscosify and harden. | 2010-06-03 |
| 20100137474 | Composite Nanoparticles, Nanoparticles and Methods for Producing Same - In various aspects provided are methods for producing a nanoparticle within a cross-linked, collapsed polymeric material. In various embodiments, the methods comprise (a) providing a polymeric solution comprising a polymeric material; (b) collapsing at least a portion of the polymeric material about one or more precursor moieties; (c) cross-linking the polymeric material; (d) modifying at least a portion of said precursor moieties to form one or more nanoparticles and thereby forming a composite nanoparticle. | 2010-06-03 |
| 20100137475 | EPOXY RESIN-FORMING LIQUID PREPARATION CONTAINING INORGANIC PARTICLE - There is provided a liquid preparation for forming an epoxy resin having curing properties combining high transparency and high bending strength while maintaining advantageous handling properties as in a liquid state. A liquid preparation for forming an epoxy resin comprising: an A agent; and a B agent; wherein the A agent contains a modified epoxy resin (I) formed from at least one type of compound (i) having in a molecule thereof, at least one functional group of Formula (1): | 2010-06-03 |
| 20100137476 | DISPERSANT FOR PLASTER COMPOSITIONS - The present invention relates to the use of a polymer P as a dispersant, particularly as a liquefier, for plaster compositions as well as plaster compositions comprising the polymer P. The polymer P comprises at least one acid unit, at least one ester unit, and at least one amide unit, and the ratio of the acid units to the ester and amide units is between 2 and 6. | 2010-06-03 |
| 20100137477 | WORKABILITY OF AN AQUEOUS FORMULATION WITH A HYDRAULIC BINDER BASE USING A COMBINATION OF COMB-BRANCHED POLYMERS - The invention pertains to improving the workability of an aqueous formulation with a hydraulic binder base using a combination between at least one comb-branched copolymer having a (meth)acrylic skeleton, onto which are grafted side-chains terminated by a hydrophilic group, and at least one comb-branched copolymer having a (meth)acrylic skeleton, onto which are grafted side-chains terminated by a hydrophobic group. | 2010-06-03 |
| 20100137478 | POLYMER MICROFILLER COMPOSITES - The instant invention generally provides polymer microfiller composite comprising a molecularly self-assembling material and a microfiller, and a process of making and an article comprising the polymer microfiller composite. | 2010-06-03 |
| 20100137479 | FLAME-RETARDANT POLYAMIDE COMPOSITIONS AND SHAPED ARTICLES MOLDED THEREFROM - Flame-retardant polyamide compositions that can be converted into molded shaped articles contain melamine cyanate and a novolac resin; such molded shaped articles are particularly useful in the field of electric or electronic connector technology, e.g., as circuit-breakers, switches or connectors. | 2010-06-03 |
| 20100137480 | COATING SYSTEMS COMPRISING DIOXOLANE FILM-FORMING AGENTS - Dioxolane compound film-forming agents are formulated into surface coating compositions such as paints and varnishes, in particular industrial, graphic and architectural paints, and serve as coalescence agents and/or drying retardants. | 2010-06-03 |
| 20100137481 | POLYETHYLENE MATERIALS - Certain embodiments described herein are directed to polymer compositions including a base material, a secondary material and an antioxidant. The composition also includes crystalline regions and amorphous regions with the crystalline regions comprising at least 62% by volume of the composition. In some embodiments, the base material is an ultra high molecular weight polyethylene material and the secondary material is a polyethylene material that is different than the base material. | 2010-06-03 |
| 20100137482 | Symmetric Cyclic Phosphonate Compound, Method of Preparing the Same and Flame Retardant Styrenic Resin Composition Including the Same - Disclosed herein is a symmetric cyclic phosphonate compound represented by the following Formula 1, a method of preparing the same and a flame retardant styrenic resin composition including the same: | 2010-06-03 |
| 20100137483 | Mixture Based on a Polyisocyanate and a Solvent of Ether Ester Type, Aqueous Emulsion Obtained from this Mixture and Use of this Emulsion for the Manufacture of Coatings and Adhesives - The mixture of the invention comprises at least one cycloaliphatic polyisocyanate and at least one solvent comprising an ester function and an ether function. An aqueous emulsion can be obtained from this mixture which also comprises a compound bearing a function with a mobile hydrogen, selected from primary or secondary hydroxyl functions, phenol functions, primary and/or secondary amino functions, carboxylic functions and a thiol function or a compound containing precursor functions capable of freeing hydroxyl functions. The emulsion can be used for the manufacture of coatings on a substrate of cement, of wood or especially of leather, and also for the manufacture of adhesives. | 2010-06-03 |
| 20100137484 | OPTICALLY ANISOTROPIC COMPOUND AND RESIN COMPOSITION COMPRISING THE SAME - Disclosed is a compound having high optical anisotropy and high compatibility with a polymer resin, which is represented by Formula 1 and necessarily has at least one meta substituent. Also, a resin composition including the compound and a polymer resin, and an optical member including the resin composition are disclosed. Since the compound represented by Formula 1 is an anisotropic compound having high compatibility with a polymer resin and high optical anisotropy, in the case of an optical member obtained by using a polymer resin composition including the compound represented by Formula 1, there is no phase separation, and it is possible to achieve a required optical characteristic with only a small amount thereof. | 2010-06-03 |
| 20100137485 | ADHESIVES - Adhesive, comprising silanized, structurally modified, pyrogenically prepared silicas containing on their surface fixed vinyl groups or vinylsilyl groups, with hydrophobic groups, such as trimethylsilyl and/or dimethylsilyl and/or monomethylsilyl, additionally being fixed on the surface. | 2010-06-03 |
